相关实验视频

Updated: May 15, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

作为预防和治疗血栓形成的药物点的XI因子

Nathaniel B Wayne¹, Sarah B Schaidle², Craig J Beavers³

¹Pharmacy Department, Wellstar MCG Health 1481 Laney Walker Blvd, POB One, Suite 1400 Augusta, GA 30912 Nathaniel.Wayne@wellstar.org; (706) 721-2639.

Journal of cardiovascular pharmacology

|April 8, 2025

概括

十一因子 (FXI) 抑制提供了一种新的方法,可以在不增加出血风险的情况下预防血栓形成. 各种针对FXI的药物正在临床试验中,用于治疗急性冠状动脉综合征和静脉血栓栓塞等疾病.

科学领域:

药理学和血栓瘤研究研究
药物开发和临床试验

背景情况:

最佳的抗凝血需要平衡血栓形成的预防和出血风险.
十一因子 (FXI) 是抗凝治疗的潜在新目标.
抑制FXI可以提供抗血栓益处,降低出血风险.

研究的目的:

探索第十一个因子 (FXI) 抑制的治疗潜力.
审查目前针对FXI的药物开发机制.
总结FXI抑制剂的临床试验应用和正在进行的研究领域.

主要方法:

对各种FXI抑制机制的审查:反感性寡核酸,单克隆抗体,小分子,和体.
对FXI抑制剂用于心血管事件,静脉血栓栓塞和中风的二次预防的临床试验数据的分析.
在特殊人群中确定正在进行的研究,包括末期病,癌症和COVID-19.

主要成果:

针对FXI的多种药物模式正在调查中.
临床试验正在评估FXI抑制剂用于主要血栓状况的二次预防.
研究正在扩大,包括具有特定伴随性疾病的高风险患者队列.

结论:

十一因子 (FXI) 抑制是一种有前途的新型抗血栓策略.
目前正在开发和在临床环境中测试各种药理学方法.
需要进一步的研究来确定FXI抑制剂在各种患者群体和临床适应症中的疗效和安全性.

关键词:

这是一种抗凝血药物.这是一种抗血栓的抗血栓药物.流血出血流血出血凝血级联是凝血级联的一个过程.血液静止血液静止血液静止

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...